CannTrust Holdings Inc. closed at $1.04 in the latest trading session, marking a +0.97% move from the prior day. This move outpaced the S&P 500's daily gain of 0.26%. Elsewhere, the Dow gained 0.02%, while the tech-heavy Nasdaq added 0.48%.
Prior to today's trading, shares of the company had gained 15.07% over the past month. This has outpaced the Medical sector's gain of 4.97% and the S&P 500's gain of 5.19% in that time.
Wall Street will be looking for positivity from CTST as it approaches its next earnings report date.
Investors should also note any recent changes to analyst estimates for CTST. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CTST currently has a Zacks Rank of #2 (Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 59, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Image: Bigstock
CannTrust Holdings Inc. (CTST) Outpaces Stock Market Gains: What You Should Know
CannTrust Holdings Inc. closed at $1.04 in the latest trading session, marking a +0.97% move from the prior day. This move outpaced the S&P 500's daily gain of 0.26%. Elsewhere, the Dow gained 0.02%, while the tech-heavy Nasdaq added 0.48%.
Prior to today's trading, shares of the company had gained 15.07% over the past month. This has outpaced the Medical sector's gain of 4.97% and the S&P 500's gain of 5.19% in that time.
Wall Street will be looking for positivity from CTST as it approaches its next earnings report date.
Investors should also note any recent changes to analyst estimates for CTST. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CTST currently has a Zacks Rank of #2 (Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 59, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.